In contrast, cobimetinib not only inhibits ERK1/2 phosphorylation but also retains the inhibitory effect of phosphorylated MEK1/2 [605], whereas binimetinib exhibits clinical activity in both BRAF-mutated and NRAS-mutated melanoma [606]. The gene discussed is BRAF; the disease is melanoma.